Takeda Pharmaceutical (NYSE:TAK) Sets New 12-Month High – Should You Buy?

Takeda Pharmaceutical Company Limited (NYSE:TAK)’s share price hit a new 52-week high during trading on Monday . The company traded as high as $15.22 and last traded at $15.20, with a volume of 561724 shares traded. The stock had previously closed at $15.01.

Takeda Pharmaceutical Stock Performance

The firm has a market capitalization of $48.25 billion, a price-to-earnings ratio of 37.91, a P/E/G ratio of 0.24 and a beta of 0.46. The company has a quick ratio of 0.72, a current ratio of 1.31 and a debt-to-equity ratio of 0.63. The stock has a 50-day moving average price of $13.83 and a 200 day moving average price of $13.91.

Takeda Pharmaceutical (NYSE:TAK) last posted its earnings results on Thursday, January 30th. The company reported $0.42 earnings per share for the quarter, topping the consensus estimate of $0.34 by $0.08. Takeda Pharmaceutical had a return on equity of 9.39% and a net margin of 4.53%. On average, analysts forecast that Takeda Pharmaceutical Company Limited will post 1.64 EPS for the current year.

Institutional Investors Weigh In On Takeda Pharmaceutical

Several institutional investors have recently added to or reduced their stakes in the business. Forum Financial Management LP lifted its stake in Takeda Pharmaceutical by 133.7% during the fourth quarter. Forum Financial Management LP now owns 114,324 shares of the company’s stock worth $1,514,000 after purchasing an additional 65,399 shares during the last quarter. Toronto Dominion Bank purchased a new stake in Takeda Pharmaceutical during the fourth quarter worth approximately $6,760,000. GTS Securities LLC purchased a new stake in Takeda Pharmaceutical during the fourth quarter worth approximately $1,292,000. Vise Technologies Inc. lifted its stake in Takeda Pharmaceutical by 3.1% during the fourth quarter. Vise Technologies Inc. now owns 34,635 shares of the company’s stock worth $459,000 after purchasing an additional 1,026 shares during the last quarter. Finally, Voloridge Investment Management LLC lifted its stake in Takeda Pharmaceutical by 150.6% in the fourth quarter. Voloridge Investment Management LLC now owns 340,953 shares of the company’s stock valued at $4,514,000 after buying an additional 204,911 shares during the last quarter. Hedge funds and other institutional investors own 9.17% of the company’s stock.

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.